Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 20 de 1193 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Hawkes N. Statin initiation is unrelated to cardiovascular risk score, finds study.. BMJ 2017;359:j4898. [Ref.ID 102110]
2. Cita con resumen
McGettigan P, Ferner RE. PCSK9 inhibitors for hypercholesterolaemia. BMJ 2017;356:j188. [Ref.ID 101397]
5.Enlace a cita originalTiene citas relacionadas
6.Tiene citas relacionadas
Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, Demets D, Evans S, Law M, McMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercok P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532-61. [Ref.ID 100988]
7.Enlace a cita originalTiene citas relacionadas
Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. JAMA 2016;316:1979-81. [Ref.ID 100987]
8.Enlace a cita originalTiene citas relacionadas
Greenland P, Bonow RO. Interpretation and use of another statin guideline. JAMA 2016;316:1977-9. [Ref.ID 100986]
9.Enlace a cita originalTiene citas relacionadas
Gurwitz JH, Go AS, Fortmann SP. Statins for primary prevention in older adults: uncertainty and the need for more evidence. JAMA 2016;316:1971-2. [Ref.ID 100985]
10.Enlace a cita originalTiene citas relacionadas
Thompson PD. What to believe and do about statin-associated adverse efects. JAMA 2016;316:1969-70. [Ref.ID 100984]
11.Enlace a cita originalTiene citas relacionadas
Rodríguez F, Harrington RA. Cholesterol, cardiovascular risk, statins, PCSK9 inhibitors, and the future of LDL-C lowering. JAMA 2016;316:1967-8. [Ref.ID 100983]
12. Cita con resumen
Godlee F. Statins: we need an independent review. BMJ 2016;354:i4992. [Ref.ID 100746]
13.Enlace a cita originalTiene citas relacionadas
Baigent C. Aspirin for disease prevention: public policy or personal choice?. Ann Intern Med 2016;164:846-7. [Ref.ID 100467]
14.Enlace a cita originalTiene citas relacionadas
Bibbins-Domingo K, on behalf of the U.S. Preventive Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2016;164:836-45. [Ref.ID 100466]
15.Enlace a cita originalTiene citas relacionadas
Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:826-35. [Ref.ID 100465]
16.Enlace a cita originalTiene citas relacionadas
Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DSM, Anderson ML. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:814-25. [Ref.ID 100464]
17.Enlace a cita originalTiene citas relacionadas
Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:804-13. [Ref.ID 100463]
18.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dehmer SP, Maciosek MV, Flottemesch TJ, LaFrance AB, Whitlock EP. Aspirin for the primary prevention of cardiovascular disease and colorectal cancer: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:777-86. [Ref.ID 100462]
19. Cita con resumen
Ezquerra Pérez G, Martín de la Nava MA, Álvarez-Cienfuegos A, Montaño Barrientos A, Baquero Barroso MJ, Rubio Núñez PL, Gómez Santana MC, Gavilán Moral E, Candela Marroquín E, Sánchez Robles GA. Revisión GRADE de estatinas en población con = 90% en prevención primaria cardiovascular. Sección 3: Efectos adversos. II. Miopatías.. Grupo Evalmed-GRADE 2016:21 de enero. [Ref.ID 99983]
20. Cita con resumen
Toledo E, Salas-Salvadó J, Donat-Vargas C, Buil-Cosiales P, Estruch R, Ros E, Corella D, Fitó M, Hu FB, Arós F, Gómez-Gracia E, Romaguera D, Ortega-Calvo M, Serra-Majem L, Pintó X, Schröder H, Basora J, Sorlí JV, Bulló M, Serra-Mir M, Martínez-González MA. Mediterranean diet and invasive breast cancer risk among women at high cardiovascular risk in the PREDIMED trial. A randomized clinical trial. JAMA Intern Med 2015;175:1752-60. [Ref.ID 99462]
Seleccionar todas
 
 1 a 20 de 1193 siguiente >>